对环素D1的要求是癌中细胞自主HIF2依赖的基础
Nitin H Shirole1, Devishi Kesar2, Yenarae Lee3
1Dana-Farber Cancer Institute, Boston, MA, United States.
Cancer discovery
|April 3, 2025
概括
维持cyclin D1表达赋予抗 belzutifan,清晰细胞癌 (ccRCC) 的治疗方法. 这种耐药性涉及酶依赖和自主活动的Cyclin D1.1.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 清细胞癌 (ccRCC) 是由于VHL基因失活而导致HIF2a稳定导致的.
- 贝尔祖提凡是一种HIF2a抑制剂,可以治疗ccRCC,但它面临着新的挑战和获得的耐药性.
- 与RNA复合的HIF2a调节了对ccRCC进展至关重要的基因转录.
研究的目的:
- 在ccRCC中识别HIF2a响应基因,从而赋予ccRCC中对贝尔祖提凡的耐药性.
- 阐明CCND1 (Cyclin D1) 促进抗性的机制.
- 为了研究Cdk4/6,pRB及其对应物在Cyclin D1介导的耐药性中的作用.
主要方法:
- 克里斯普尔激活 (CRISPRa) 屏幕在ccRCC细胞系中,该细胞系对贝尔祖提凡类似物有抗性.
- 分析CCND1表达及其对HIF2a依赖性的影响.
- 评估Cyclin D1在耐药性中的作用,使用野生类型和酶缺陷变体,以及细胞系与枯竭的pRB家族成员.
主要成果:
- 持续表达的HIF2a基因CCND1赋予HIF2a独立性和抗贝尔苏提凡的耐药性.
- 环素D1的耐药性促进活性需要Cdk4/6激活,但超出了pRB酸化.
- 一种酶缺陷的Cyclin D1变体部分克服了贝尔祖提凡的作用,表明酶独立的作用.
结论:
- CCND1是ccRCC中贝尔祖提凡耐药性的关键调解者.
- 环素D1通过Cdk4/6-依赖的pRB对应物酸化和基因酶独立的机制促进ccRCC的生长.
- 针对CCND1或与之相关的途径可以克服ccRCC中的贝尔祖提凡耐药性.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Positive Regulator Molecules
5.3K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.3K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Adaptive Mechanisms in Cancer Cells
5.6K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.6K


